A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety/tolerability and determine the Japanese
recommended dose (RD) of bortezomib administered as a once-daily intravenous bolus twice
weekly for 2 consecutive weeks(Days 1, 4, 8, and 11) followed by a 10-day rest period (Days
12 to 21) in Japanese patients with relapsed or refractory multiple myeloma.